Table 1 Summary of the studies reporting on solitary splenic metastases from NPC
Year | First author | Type of study | Number and type of patients considered | Patients with solitary splenic metastases from NPC | Patient’s age, sex (M, F) | Comorbidity | Primary treatment for NPC | Disease-free survival after primary treatment | Methods of detection of splenic metastasis | Treatment for solitary splenic metastasis | Confirmatory histology of NPC splenic metastases | Overall survival (status at last follow-up) | Relapse after splenic surgery |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2000 | Lam & Tang [3] | CS | 92 patients with splenic metastases | 1 (1.1 %) | M | NS | NS | NS | NS | - Splenectomy | UCNT | NS | NS |
2013 | Suh et al. [38] | CR | 1 non-keratinizing NPC | 1 | 35 years old, M | EBV | - Neoadjuvant chemotherapy (cysplatin and 5-fluorouracil) - Left medial maxillectomy with left modified radical neck dissection - Adjuvant radiochemotherapy (cysplatin and 63 Gy) | 7 months | FDG-PET/CT FNA biopsy | - Systemic chemotherapy (docetaxel and cysplatin) - Laparoscopic splenectomy | UCNT | 5 months (alive) | Nil |
2015 | Abu-Zaid et al. [27] | CR | 1 NPC | 1 | 26 years old, M | NS | - Surgical resection - Adjuvant radiochemotherpay | 6 years | CT FNA biopsy | - Splenectomy | UCNT | 12 months (alive) | Nil |
2015 | Present study | CR | 1 NPC | 1 | 56 years old, M | Smoker, EBV | - Neoadjuvant chemotherapy (docetaxel, carboplatin, and 5-Fluorouracil) - Radiotherapy (70 Gy) | 3 months | PET/CT | - Laparoscopic splenectomy | UCNT | 4 months (alive) | Nil |